Health Trials

Clinical trials

3

Search and review clinical trials. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Not yet recruiting

IKS04 Regimen in Advanced Solid Tumors That Express CA242

This study will evaluate the safety, tolerability, anti-tumor activity, immunogenicity, pharmacokinetics and pharmacodynamics of the IKS04 Regimen and identify a recommended phase 2 dose (RP2D) or recommended dose for further evaluation in expansion (RDE). The regimen includes Isumab04 (unconjugated antibody) followed by the IKS04 antibody-drug conjugate, both directed against the CA242 (CanAg) tumor-associated antigen and administered intravenously (IV) in patients with advanced solid cancers.

Participants needed: 120
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Iksuda Therapeutics Ltd.Updated: Jul 31, 2026Locations: 4
Eligibility criteria

Advanced or metastatic CRC, BTCs, GEA, and PDAC that is histologically or cytolo... [+12]

Significant symptomatic chronic obstructive pulmonary disease (COPD), as assesse... [+18]

Read more
Status: Recruiting

IKS03 in Patients With Advanced B Cell Non-Hodgkin Lymphomas

This first-in-human study will evaluate the recommended dose for further clinical development, safety, tolerability, antineoplastic activity, immunogenicity, pharmacokinetics and pharmacodynamics of IKS03, a CD19 targeting antibody-drug conjugate, in patients with advanced B cell non-Hodgkin lymphoma (NHL).

Participants needed: 140
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Iksuda Therapeutics Ltd.Updated: Jul 29, 2026Locations: 13
Eligibility criteria

Males or females, ≥ 18 years of age [+14]

Women who are pregnant or intending to become pregnant before, during, or within... [+63]

Read more
Status: Recruiting

IKS014 in Advanced Solid Tumors That Express HER2

This study will evaluate the recommended dose for further clinical development, safety, tolerability, anti-tumor activity, immunogenicity, pharmacokinetics and pharmacodynamics of IKS014, a HER2 targeting antibody-drug conjugate, in patients with advanced solid tumors.

Participants needed: 165
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Iksuda Therapeutics Ltd.Updated: May 8, 2026Locations: 13
Eligibility criteria

HER2 positive solid tumors with expression defined as IHC3+, IHC2+/ISH+, or low... [+17]

History of (noninfectious) ILD/pneumonitis that required steroids, has current I... [+15]

Read more